October 27, 2011 -- Lansen Pharmaceutical Holdings obtained exclusive China rights to a rheumatoid treatment from Ethypharm SA, a French pharma. Headquartered in Hong Kong, Lansen manufactures and distributes western-style drugs in mainland China, with a focus on disease-modifying anti-rheumatic drugs (DMARDs). The license gives Lansen the right to distribute ketoprofen/omeprazole slow-release capsules for more than ten years. More details....
Stock Symbol: (HKEX: 503)
